Clinical trial NCT01552980: Efficacy and Safety Study of a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
Official title: A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Gastric Adenocarcinoma
Keywords: Gastric cancer
Adenocarcinoma
SOX
Lead sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2012-03-13
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, phase II study to evaluate the efficacy and safety of a modified regimen of oxaliplatin and S-1 on unresectable gastric adenocarcinoma in the first-line therapy.

Detailed description: Primary endpoint: Overall Response Rate

Secondary endpoint: Time to progression, overall survival, safety data

Eligibility criteria: Inclusion Criteria:

* Signed written informed consent;
* Patients with histologically or cytologically confirmed unresectable gastric adenocarcinoma whose ECOG performance status are 0-2;
* Presence of measurable disease by radiographic study (including CT or MRI scan, or chest x-ray) or physical examination;
* At least 3 weeks since last major surgery;
* At least 12 months since last adjuvant chemotherapy;
* At least 6 weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is NOT expected;
* Patients who have received palliative radiotherapy must have recovered from any reversible toxic effects e.g. nausea and vomiting caused by radiation of fields;
* Patients with reproductive potential must use effective BC;
* Required Screening Laboratory Criteria:

  * Hemoglobin 90g/L
  * WBC 3.5 x 109/L
  * Neutrophils 1.5 x 109/L
  * Platelets 100 x 109/L
  * Creatinine 133 umol/L and creatinine clearance 60 mL/min
* A probable life expectancy of at least 6 months;

Exclusion Criteria:

* Brain metastases;
* Female of childbearing potential, pregnancy test is positive;
* Concomitant malignancies or previous malignancies other than colorectal cancer within the last five years, with the exception of adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, or low grade prostate cancer;
* Active infection;
* Concurrent severe medical problems unrelated to the malignancy, which would significantly limit full compliance with the study or expose the patient to extreme risk;
* Sexually active patients refusing to practice adequate contraception;
* Patients with conditions which might affect absorption of an oral drug (for example intermittent obstruction) unless discussed and agreed with principal investigator;
* History of grade 3 or 4 toxicity to fluoropyrimidines;
* Pre-existing neuropathy ≥ NCI CTC grade 2.

Primary outcomes:
measure: Overall response rate according to RECIST 1.1
timeFrame: One year
Secondary outcomes:
measure: Time to progression
timeFrame: One year
measure: overall survival
timeFrame: one year
measure: safety data of this regimen
timeFrame: one year
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sixth Affiliated Hospital of Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Sixth Affiliated Hospital, Sun Yat-sen University
name: Jian Xiao
role: PRINCIPAL_INVESTIGATOR
References: